361 related articles for article (PubMed ID: 32770672)
1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Lima JJ; Thomas CD; Barbarino J; Desta Z; Van Driest SL; El Rouby N; Johnson JA; Cavallari LH; Shakhnovich V; Thacker DL; Scott SA; Schwab M; Uppugunduri CRS; Formea CM; Franciosi JP; Sangkuhl K; Gaedigk A; Klein TE; Gammal RS; Furuta T
Clin Pharmacol Ther; 2021 Jun; 109(6):1417-1423. PubMed ID: 32770672
[TBL] [Abstract][Full Text] [Related]
2. Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center.
Cicali EJ; Elchynski A; Thomas CD; Alam B; Dalton R; Davis R; Eken E; Estores D; Nguyen K; Cavallari LH; Wiisanen K
Am J Health Syst Pharm; 2023 Jul; 80(15):994-1003. PubMed ID: 37166240
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
El Rouby N; Lima JJ; Johnson JA
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):447-460. PubMed ID: 29620484
[TBL] [Abstract][Full Text] [Related]
4. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
[TBL] [Abstract][Full Text] [Related]
5. New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump Inhibitors.
Sabet S; McGhee JE
J Pediatr Gastroenterol Nutr; 2021 May; 72(5):697-699. PubMed ID: 33720093
[TBL] [Abstract][Full Text] [Related]
6. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
Cicali EJ; Blake K; Gong Y; Mougey EB; Al-Atrash H; Chambers N; Denham J; Evans J; George DE; Gomez R; Palomo P; Taufiq S; Johnson JA; Lima JJ; Franciosi JP
Clin Transl Sci; 2019 Mar; 12(2):172-179. PubMed ID: 30341969
[TBL] [Abstract][Full Text] [Related]
7. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.
Furuta T; Sugimoto M; Shirai N
Mol Diagn Ther; 2012 Aug; 16(4):223-34. PubMed ID: 22873740
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.
Lima JJ; Franciosi JP
Pharmacogenomics; 2014 Aug; 15(11):1405-16. PubMed ID: 25303292
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
10. Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.
Harris DM; Stancampiano FF; Burton MC; Moyer AM; Schuh MJ; Valery JR; Bi Y
Dig Dis Sci; 2021 Dec; 66(12):4120-4127. PubMed ID: 33475867
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 polymorphism influences Helicobacter pylori eradication.
Kuo CH; Lu CY; Shih HY; Liu CJ; Wu MC; Hu HM; Hsu WH; Yu FJ; Wu DC; Kuo FC
World J Gastroenterol; 2014 Nov; 20(43):16029-36. PubMed ID: 25473155
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
Chaudhry AS; Kochhar R; Kohli KK
Indian J Med Res; 2008 Jun; 127(6):521-30. PubMed ID: 18765869
[TBL] [Abstract][Full Text] [Related]
14. Update on the pharmacogenomics of proton pump inhibitors.
Hagymási K; Müllner K; Herszényi L; Tulassay Z
Pharmacogenomics; 2011 Jun; 12(6):873-88. PubMed ID: 21692617
[TBL] [Abstract][Full Text] [Related]
15. Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?
Ormeci A; Emrence Z; Baran B; Soyer OM; Gokturk S; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1795-7. PubMed ID: 27212172
[TBL] [Abstract][Full Text] [Related]
16. A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens.
Chevalier R; Attard T; Van Driest SL; Shakhnovich V
Expert Opin Drug Metab Toxicol; 2023 Feb; 19(2):53-56. PubMed ID: 36919492
[No Abstract] [Full Text] [Related]
17. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Furuta T; Sugimoto M; Shirai N; Ishizaki T
Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.
Yang JC; Lin CJ
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):29-41. PubMed ID: 19968574
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of the proton pump inhibitors: a systematic review.
Chong E; Ensom MH
Pharmacotherapy; 2003 Apr; 23(4):460-71. PubMed ID: 12680476
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
